… about the pharmacokinetic behavior of the modified-release formulation of DP under
hypochlorhydric condition. The acidic pH-modifiers are commonly used to manipulate the pH in …

… microenvironmental pH. In addition, evaluating the release behavior of pH-modifiers from …
A better understanding of the pharmacokinetic and safety characteristics of nanoformulation …

… the improved dissolution and consistent pharmacokinetic behavior of CAR using ASD system
with pH-modifiers under hypochlorhydric conditions. The pH-modification technologies are …

… pH-modifier for solubilizing DP, possibly leading to improved pharmacokinetic behavior of
DP … Pharmacokinetic behavior of DP was evaluated after oral administration of DPG and DPG/…

… This analysis also highlights a polyprotic pH modifier’s superiority to a monoprotic pH modifier
for drug compounds with high intrinsic solubility, high dose, and/or more basic pK a . It is …

… In addition, DPX pharmacokinetic behavior was studied after buccal administration of the
selected optimal formulation to rats in comparison to an oral reference product. …

… as pH-modifiers. The purpose of this study is to (A) develop a solid oral formulation containing
KZ as a model compound and organic acids as pH-modifiers… a rat pharmacokinetic model. …

… pharmacokinetic behavior of ondansetron was studied. After oral administration of ondansetron
without pH modulating agent (F0) and with pH … compare the pharmacokinetic behavior of …

… The in vivo pharmacokinetics of the pH M -SDs tablets were also studied in beagle dogs …
modifiers affect the behavior of the drug in solid dosage forms by promoting the hydrophilic …

… acidic pH modifier had similarity factor (f 2 ) ≥ 50 proving the pH independent release of AMS.
The pharmacokinetic … AMS imparted by the pH-modified matrix tablet containing Labrasol. …